ORIGINAL RESEARCH

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)

Giovanni Adami, Angelo Fassio, Maurizio Rossini, Davide Bertelle, Francesca Pistillo, Camilla Benini, Ombretta Viapiana, Davide Gatti

ABSTRACT

Introduction Glucocorticoids are still a mainstream of rheumatoid arthritis (RA) treatment. Reducing glucocorticoids should be attempted in all patients. However, choosing the right tapering strategy is challenging. The primary aim of our study is to determine the dose–response association between glucocorticoid tapering and risk of flare in RA.

Methods We conducted a case-crossover study to determine the factors associated to higher risk of flare in patients with RA. In case-crossover studies time-varying factors are assessed before events (hazard periods) and before control periods. We defined hazard periods as the 6 months immediately preceding flares of RA. Control periods were the 6 months prior to visits without flare. Exposure of interest was the tapering of glucocorticoids to various doses.

Results 508 patients with RA were included in the study and 267 (52.5%) had at least a flare and served as the case-crossover study population. 1545 visits were available for analysis and 345 (22.3%) flares were recorded. Discontinuation of glucocorticoids (ie, tapering to doses of 0 mg/day) and tapering to 0–2.5 mg/day was associated with higher risk of flare (adjusted OR (aOR) of 1.45, 95% CI: 1.13 to 2.24 and aOR of 1.37; 95% CI: 1.06 to 2.01, respectively). Tapering to doses >2.5 mg/day was not associated with significantly higher risk of flare.

Conclusions We found that tapering to doses of >2.5 mg/day was generally effective in terms of risk of flare. Flare risk was higher when glucocorticoids were tapered to doses ≤2.5 mg/day. Our study might help design new tapering strategies in patients with RA on biological disease-modifying antirheumatic drugs.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic condition characterised by periods of remission alternated with disease reactivations (ie, flares). Many factors have been associated with flares, including infections, treatment discontinuation and other environmental factors, including air pollution exposure. 1–4 Treatment options for RA are rapidly expanding but glucocorticoids are still largely prescribed to reduce inflammation and control disease activity. 5 Tapering glucocorticoids to the lowest dose possible is strongly encouraged by the 2019 European League Against Rheumatism (EULAR) recommendations for the management of RA. 6 Moreover, the need for rapid glucocorticoid dose reduction and possibly discontinuation is even more clearly stressed in the recent update of the recommendations. 7 Yet, tapering strategies are mostly based on expert opinion or personal belief and it is unclear whether chronic low-dose glucocorticoid treatment can provide substantial benefits that overcome the harms of such approach. 8–10 Approximately 50% of patients with early RA attain glucocorticoids discontinuation at 3 years but about 30% of them will have a flare within the next 6 months from discontinuation. 11 Indeed, tapering and discontinuing...
glucocorticoids has been associated with higher risk of flare but the dosage at which the flare happens is unpredictable and mostly not known. In addition, the EULAR definition for low-dose glucocorticoids (ie, ≤7.5 mg/day) is arbitrary and based on questionable assumptions, which are not related to efficacy on disease activity but mostly on common sense and frequency of adverse events. The primary objective of the present study is to describe and determine the dose–response association between glucocorticoid tapering and risk of flare in RA.

METHODS

We collected demographic, clinical and laboratoristic data on patients with RA from the outpatient service of the Rheumatology Unit of the University of Verona between January 2016 and January 2020. Patients were seen, as per clinical practice, every 3–4 months. We included patients with: (1) diagnosis of RA according to ACR/EULAR 2010 classification criteria and (2) initiating treatment biological disease-modifying antirheumatic drugs (bDMARDs). The following clinical, radiological and demographic parameters were collected: gender, age, weight, height, Disease Activity Score on 28 joints (DAS28), C reactive protein (CRP) serum levels, X-ray of hands and feet (at baseline and every 6–12 months), disease duration prior to bDMARD initiation, glucocorticoids and treatment with conventional and biological therapies including methotrexate, leflunomide, infliximab, etanercept, adalimumab, golimumab, certolizumab pegol, rituximab, abatacept, tocilizumab, baricitinib and tofacitinib.

We conducted a case–crossover study in which every patient serves as its own control. In case–crossover study time-varying factors are assessed in hazard periods (before an ‘event’) and in control periods. In such scheme every patient could have multiple hazard periods and control periods. Case–crossover design permits to control for time-invariant and between patients’ factors (figure 1). We defined hazard periods as the 6 months (and 3-month periods in sensitivity analysis) immediately preceding a flare of disease. Flare was defined as DAS28–CRP increase ≥1.2 and current DAS28–CRP ≥3.2 (OMERACT definition). Other definitions of flare were employed in sensitivity analyses. The time-variant independent variable of interest (exposure) was the tapering of glucocorticoids during the hazard periods versus control periods. Tapering of glucocorticoids was defined as the reduction of glucocorticoids dose from prior visit. Glucocorticoid tapering was further categorised into (1) tapering to 0 mg/day (ie, discontinuation), (2) tapering to 0–2.5 mg/day, (3) tapering to 2.5–5 mg/day, (4) tapering to 5–7.5 mg/day and (5) tapering to ≥7.5 mg/day. Conditional logistic regression analysis was employed to determine the association between tapering of glucocorticoids with flare risk. We adjusted, as per case–crossover design, for relevant time-varying confounders (ie, biological Disease Modifying Anti-Rheumatic Drug (bDMARD) use, conventional synthetic (cs)DMARD use, Non-Steroidal Anti-Inflammatory Drugs (NSAID) use and disease activity). Indeed, patients were allowed to switch bDMARD or csDMARD during the study and can use NSAID medications for pain control. Smoothed curve with restricted cubic splines with knots at each glucocorticoid tapering dose was employed to describe the dose–response association between glucocorticoid tapering and risk of flare. Differences were considered significant at p<0.05. All statistical analyses were performed using SPSS V.26 (SPSS, Chicago, Illinois, USA) and GraphPad Prism V.9.3.1 (GraphPad Software, San Diego, California, USA). The study was conducted according to the protocol BIOREVE 534CESC approved by the University of Verona local Ethic Committee, in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

RESULTS

A total of 508 patients were included in the study. Among the cohort, 267 (52.5%) patients had at least a flare (DAS28–CRP increase ≥1.2 and current DAS28–CRP ≥3.2 between two consecutive visits) during the follow-up and served as the case–crossover study population. A total of 1545 visits were available for analysis and 345 (22.3%) flares were recorded. Two hundred and sixteen (80.9%) patients were on glucocorticoids at baseline. Tapering of glucocorticoids was done in 176 (81.5% of 216) patients and discontinuation was attained, at least once, in 125 (57.8% of 216) patients. Definitive discontinuation was achieved in 101 (46.7%) patients at a median follow-up of 884 days (IQR: 700–976 days). Among the overall cohort 320 (62.9%) patients switched bDMARD at least once and 102 (20.1%) switched bDMARD more than once. General characteristics of the overall and flare cohorts are presented in table 1.

The adjusted ORs (aORs) for flare compared with no tapering were as follows: for tapering to 0 mg/day (ie, discontinuation) 1.45 (95% CI: 1.13 to 2.24), for tapering to 0–2.5 mg/day 1.97 (95% CI: 1.06 to 2.01), for tapering to 2.5–5 mg/day 1.29 (95% CI: 0.98 to 1.90), for tapering to 5–7.5 mg/day 0.98 (95% CI: 0.68 to 1.61) and for tapering to ≥7.5 mg/day 0.89 (95% CI: 0.39 to 2.10). Figure 2 depicts the smoothed line for dose–response association between glucocorticoid tapering and risk of flare. Apparently, tapering the doses to >2.5 mg/day did
not result in an increased risk of flare. Similar results were found when we applied a different flare definition (DAS28–CRP increase >1 and current DAS28–CRP ≥3.2), data not shown.

**DISCUSSION**

Herein, we conducted a case-crossover study design aimed to determine the dose–response association between glucocorticoids tapering and risk of flare in patients with RA on biologics. In aggregate, we found that tapering to doses above 2.5 mg/day of prednisone was generally effective in terms of flare risk in patients receiving bDMARDs. We found an apparent threshold at above 2.5 mg/day for an increased risk of flares despite CIs were somehow wide and no definitive conclusion can be drawn. The vast majority of patients in our study were on glucocorticoids at baseline and most of these tried tapering the dose through the follow-up, reflecting a good application of EULAR recommendations.

Patients were allowed to switch or swap bDMARD during follow-up. *P<0.05.

bDMARD, biological disease-modifying antirheumatic drug; cDMARD, conventional disease modifying antirheumatic drug; CRP, C reactive protein; DAS28, Disease Activity Score on 28 joints; VAS, visual analogue scale.
patients with RA, further highlighting the generalisability of our results. Indeed, glucocorticoids withdrawal might be challenging in many patients due to recurrent disease flares.

Reducing glucocorticoids to doses $\leq 2.5 \text{mg/day}$ was associated with higher risk of flare. Such finding is somehow in line with other studies. As an example, in the Steroid ElimiNation In Rheumatoid Arthritis (SEMIRA) study patients with RA were randomised to receive tocilizumab and fixed dose of glucocorticoids or tocilizumab with glucocorticoids tapered until discontinuation over 6 months. Interestingly, most of the flares in the tapering group of the SEMIRA study were reported at doses between 2 mg/day and 0 mg/day. The authors speculated that the latter finding might be due either to a delayed effect of tapering higher doses or that some patients still respond to lower glucocorticoid doses but do not tolerate discontinuation. Our finding might point towards the second hypothesis.

Our results might have immediate clinical fallouts. Glucocorticoids are associated with relevant adverse events, which strictly depends on dose. Treating chronically with $< 2.5 \text{mg/day}$ of prednisone equivalent might not result in better disease control, as we demonstrated, but might pose patients at greater risk of adverse events. In the Glucocorticoid LOw-dose in Rheumatoid Arthritis (GLORIA) trial patients with RA over the age of 65 years were randomised to receive 5 mg/day of prednisone or placebo. After 2 years of treatment disease activity was 0.37 points lower on prednisolone with trade-off of 24% increase in patients with mostly non-severe adverse events, which lead the authors to conclude that the harm/benefit balance of treating chronically with glucocorticoids in such population was overall positive. We have drawn a somehow similar conclusion from our analysis as regard effectiveness of chronic glucocorticoid treatment, despite our study is largely different in design and population from the GLORIA trial.

The EULAR set the threshold for low-dose glucocorticoids at 7.5 mg/day and many authors proposed to lower such threshold to 5 mg/day. Both definitions are arbitrary and, arguably, based on debatable assumption. Our results might suggest to slightly lower this threshold in patients with RA receiving bDMARDs.

Our study has strengths and limitations. To explore the causative and temporal association between glucocorticoid tapering and risk of flare, we applied a case-crossover design, which effectively controls for between-patients and time-invariant within-patients confounders. Such study design can reduce confounding by indication bias, a type of channelling bias, that commonly affects observational studies. However, our population might not be generalisable to the entire population with RA (not on bDMARDs or early RA). Indeed, patients with early disease are commonly treated with glucocorticoids and tapering of glucocorticoids towards discontinuation might be easier in such population. In addition, non-measured time-varying confounders (such as infections) might have affected our results. Indeed, it is reasonable to think that few patients might have reduced glucocorticoids in the fear of adverse events and some others might not have reduced glucocorticoids in the fear of disease relapse. In addition, we did not collect information regarding the rapidity of tapering, which might have affected the flare rate. The monocentric nature of the study might have induced some type of systematic bias related to center-specific attitudes towards tapering glucocorticoids. Multicentric studies or similar studies replicated in other cohorts are warranted to assess reproducibility of our results.

In conclusion we found that tapering glucocorticoids to doses above 2.5 mg/day was generally effective in a population of patients with RA treated with bDMARDs. Our study might help define new glucocorticoid reducing strategies, which should aim to doses between 5 and 2.5 mg/day of prednisone equivalent.

**Contributors** Conceptualisation, data curation and formal analysis: GA. Investigation: GA, AF, MR, DB, FP, CB, OV and DG. Project administration and supervision: MR. Validation: GA and MR. Writing—original draft: GA and FP. Writing— review and editing: GA, AF, MR, DB, FP, CB, OV and DG. GA is the guarantor of the work. GA accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** The study was conducted according to the protocol BIOREVE 534CEDC approved by the University of Verona local Ethic Committee, in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
REFERENCES
10 Volkmann ER, Rezai S, Tarp S, et al. We still don’t know how to taper glucocorticoids in rheumatoid arthritis, and we can do better. *J Rheumatol* 2013;40:1646–9.